CN105940004B - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- CN105940004B CN105940004B CN201580006361.XA CN201580006361A CN105940004B CN 105940004 B CN105940004 B CN 105940004B CN 201580006361 A CN201580006361 A CN 201580006361A CN 105940004 B CN105940004 B CN 105940004B
- Authority
- CN
- China
- Prior art keywords
- mmol
- pharmaceutically acceptable
- methyl
- compound
- lcms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*c1c(C=C*2)c2nc(Nc(cn[n]2[C@](CCN(C3)C4COC4)C3(F)F)c2Cl)n1 Chemical compound CC*c1c(C=C*2)c2nc(Nc(cn[n]2[C@](CCN(C3)C4COC4)C3(F)F)c2Cl)n1 0.000 description 17
- IPRDJWPLOVTMQT-UHFFFAOYSA-N CC(C(CCNC1COCC1)N1NCCC(N)=C1C)F Chemical compound CC(C(CCNC1COCC1)N1NCCC(N)=C1C)F IPRDJWPLOVTMQT-UHFFFAOYSA-N 0.000 description 1
- MNCFCPKTMZCGQD-UHFFFAOYSA-N CC(C(F)F)C1OCCNC1 Chemical compound CC(C(F)F)C1OCCNC1 MNCFCPKTMZCGQD-UHFFFAOYSA-N 0.000 description 1
- CQJNLLKOOKTIJB-DTIOYNMSSA-N CC(C)(C)OC(N(CC(C1)[n]2ncc(N=O)c2)C[C@H]1O)=O Chemical compound CC(C)(C)OC(N(CC(C1)[n]2ncc(N=O)c2)C[C@H]1O)=O CQJNLLKOOKTIJB-DTIOYNMSSA-N 0.000 description 1
- YGIPIARFNXHZEM-UHFFFAOYSA-N CC(C)(C[n]1nc(C)c([N+]([O-])=O)c1C)O Chemical compound CC(C)(C[n]1nc(C)c([N+]([O-])=O)c1C)O YGIPIARFNXHZEM-UHFFFAOYSA-N 0.000 description 1
- KPZTVIDCWKUBPC-UHFFFAOYSA-N CC(CCC1)(C1[n]1ncc(N)c1C)O Chemical compound CC(CCC1)(C1[n]1ncc(N)c1C)O KPZTVIDCWKUBPC-UHFFFAOYSA-N 0.000 description 1
- HCJKSBDGCHXLLG-XZMRHVKESA-N CC/C(/C=N)=C(\C)/NC(CCN(C1)C2COC2)C1(F)F Chemical compound CC/C(/C=N)=C(\C)/NC(CCN(C1)C2COC2)C1(F)F HCJKSBDGCHXLLG-XZMRHVKESA-N 0.000 description 1
- OLXDFVIQVISYRX-YSZBQJHXSA-N CCOc1c(cc[nH]2)c2nc(NC(C=N[C@@](C)(C2)[C@](C)(CCN(C3)C4COC4)[C@@H]3F)=C2Cl)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(NC(C=N[C@@](C)(C2)[C@](C)(CCN(C3)C4COC4)[C@@H]3F)=C2Cl)n1 OLXDFVIQVISYRX-YSZBQJHXSA-N 0.000 description 1
- YTEPHMOFURICDX-UKRRQHHQSA-N CCOc1c(cc[nH]2)c2nc(Nc(cn[n]2[C@H](CCN(C3)C4COC4)[C@@H]3F)c2Cl)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(cn[n]2[C@H](CCN(C3)C4COC4)[C@@H]3F)c2Cl)n1 YTEPHMOFURICDX-UKRRQHHQSA-N 0.000 description 1
- NZKXGGUFPRUXLE-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc2c(C)[n](CC(C)(C)O)nc2)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc2c(C)[n](CC(C)(C)O)nc2)n1 NZKXGGUFPRUXLE-UHFFFAOYSA-N 0.000 description 1
- ZLTIWEDENJXTHK-GNRKCLAOSA-N CN(CCC1N/C=C(\C=N)/[N+]([O-])=O)CC1(F)F Chemical compound CN(CCC1N/C=C(\C=N)/[N+]([O-])=O)CC1(F)F ZLTIWEDENJXTHK-GNRKCLAOSA-N 0.000 description 1
- MOSFWXHLYZHBGC-SNVBAGLBSA-N C[C@H]1N(CC[n]2ncc(OC)c2C)CCOC1 Chemical compound C[C@H]1N(CC[n]2ncc(OC)c2C)CCOC1 MOSFWXHLYZHBGC-SNVBAGLBSA-N 0.000 description 1
- VQRDCJAPAZJUMN-UHFFFAOYSA-N Cc([n](C(CCC1)C1O)nc1)c1[N+]([O-])=O Chemical compound Cc([n](C(CCC1)C1O)nc1)c1[N+]([O-])=O VQRDCJAPAZJUMN-UHFFFAOYSA-N 0.000 description 1
- BPZYLTBLBSNUNY-BYPYZUCNSA-N FC([C@H]1OCCNC1)F Chemical compound FC([C@H]1OCCNC1)F BPZYLTBLBSNUNY-BYPYZUCNSA-N 0.000 description 1
- BNPOEVOYZGKURM-UHFFFAOYSA-N O=Nc1c(C2CC2)[n](C2CCOCC2)nc1 Chemical compound O=Nc1c(C2CC2)[n](C2CCOCC2)nc1 BNPOEVOYZGKURM-UHFFFAOYSA-N 0.000 description 1
- JHBIUGWXJOTGAV-ZETCQYMHSA-N [O-][N+](c1c[n]([C@@H]2CNCCC2)nc1)=O Chemical compound [O-][N+](c1c[n]([C@@H]2CNCCC2)nc1)=O JHBIUGWXJOTGAV-ZETCQYMHSA-N 0.000 description 1
- IHXWAAFYDDYHFU-SSDOTTSWSA-N [O-][N+](c1c[n]([C@H]2C[N-]CCC2)nc1)=O Chemical compound [O-][N+](c1c[n]([C@H]2C[N-]CCC2)nc1)=O IHXWAAFYDDYHFU-SSDOTTSWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000139 | 2014-01-29 | ||
| CNPCT/CN2014/000139 | 2014-01-29 | ||
| PCT/CN2015/000055 WO2015113452A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105940004A CN105940004A (zh) | 2016-09-14 |
| CN105940004B true CN105940004B (zh) | 2018-02-02 |
Family
ID=53756224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580006361.XA Expired - Fee Related CN105940004B (zh) | 2014-01-29 | 2015-01-28 | 化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10087186B2 (enExample) |
| EP (1) | EP3099695B1 (enExample) |
| JP (1) | JP6422986B2 (enExample) |
| KR (1) | KR20160106622A (enExample) |
| CN (1) | CN105940004B (enExample) |
| AU (2) | AU2015210593A1 (enExample) |
| CA (1) | CA2937431A1 (enExample) |
| CL (1) | CL2016001895A1 (enExample) |
| CR (1) | CR20160348A (enExample) |
| DO (2) | DOP2016000195A (enExample) |
| EA (1) | EA029774B1 (enExample) |
| ES (1) | ES2802174T3 (enExample) |
| IL (1) | IL246579B (enExample) |
| MA (1) | MA39219B1 (enExample) |
| MX (1) | MX367370B (enExample) |
| PE (1) | PE20161443A1 (enExample) |
| PH (1) | PH12016501307A1 (enExample) |
| SG (1) | SG11201605342UA (enExample) |
| UA (1) | UA118369C2 (enExample) |
| WO (1) | WO2015113452A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| CN105980388B (zh) | 2014-01-29 | 2018-01-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
| SG11201605342UA (en) | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
| CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
| CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US10023579B2 (en) | 2015-12-16 | 2018-07-17 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof |
| CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
| AU2017286653B2 (en) | 2016-06-16 | 2021-11-04 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1H-pyrazols as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders |
| BR112019015278A2 (pt) | 2017-01-25 | 2020-04-14 | Glaxosmithkline Ip Dev Ltd | compostos |
| EP3587422A4 (en) | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE |
| ES2930106T3 (es) | 2017-03-23 | 2022-12-05 | Daegu Gyeongbuk Medical Innovation Found | Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa |
| CN111433208B (zh) * | 2017-12-05 | 2023-06-30 | 奥斯考泰克公司 | 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物 |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| WO2020036437A1 (ko) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EP3856188B1 (en) * | 2018-09-25 | 2023-06-21 | Cardurion Pharmaceuticals, Inc. | Aminopyrimidine compound |
| CA3168211A1 (en) | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| CN114426542B (zh) * | 2020-10-29 | 2023-06-30 | 苏州亚宝药物研发有限公司 | 取代的二芳基胺化合物及其药物组合物、制备方法和用途 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| AR127470A1 (es) | 2021-10-27 | 2024-01-31 | H Lundbeck As | Inhibidores de lrrk2 |
| US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038572A1 (en) * | 2009-09-29 | 2011-04-07 | Glaxo Group Limited | Novel compounds |
| WO2012062783A1 (en) * | 2010-11-10 | 2012-05-18 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| WO2013079496A1 (en) * | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| WO2013139882A1 (en) * | 2012-03-21 | 2013-09-26 | F. Hoffmann-La Roche Ag | Pyrazolopyridines for treatment of parkinsons disease |
| CN103492389A (zh) * | 2011-04-21 | 2014-01-01 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
| WO2014001973A1 (en) * | 2012-06-29 | 2014-01-03 | Pfizer Inc. | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1675858A2 (en) | 2003-09-03 | 2006-07-05 | Neurogen Corporation | 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP2316927B1 (en) | 2004-10-21 | 2014-11-05 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| EA200800664A1 (ru) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | Производные пирролопиримидина в качестве ингибиторов syk |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
| PH12014500638A1 (en) | 2011-09-22 | 2017-08-09 | Pfizer | Pyrrolopyrimidine and purine derivatives |
| MX363118B (es) | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
| BR112014027117B1 (pt) | 2012-05-03 | 2022-09-06 | Genentech, Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição |
| SG11201605342UA (en) | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
| CN105980388B (zh) | 2014-01-29 | 2018-01-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
-
2015
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Ceased
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en not_active Ceased
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307A1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en not_active Expired - Fee Related
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038572A1 (en) * | 2009-09-29 | 2011-04-07 | Glaxo Group Limited | Novel compounds |
| WO2012062783A1 (en) * | 2010-11-10 | 2012-05-18 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| CN103492389A (zh) * | 2011-04-21 | 2014-01-01 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
| WO2013079496A1 (en) * | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| WO2013139882A1 (en) * | 2012-03-21 | 2013-09-26 | F. Hoffmann-La Roche Ag | Pyrazolopyridines for treatment of parkinsons disease |
| WO2014001973A1 (en) * | 2012-06-29 | 2014-01-03 | Pfizer Inc. | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105940004B (zh) | 化合物 | |
| CN108137510B (zh) | 化合物 | |
| CN110891954A (zh) | 富含亮氨酸的重复激酶2的抑制剂 | |
| CN106536525A (zh) | 化合物 | |
| CN110446700A (zh) | 化合物 | |
| CN110402247A (zh) | 化合物 | |
| CN110225910A (zh) | 化合物 | |
| HK1230172B (en) | Compounds | |
| CN101039947A (zh) | Hcv复制抑制剂 | |
| CN1759117A (zh) | 吡咯并哒嗪衍生物 | |
| HK1193089B (en) | 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180202 Termination date: 20220128 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |